Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
117 hedge funds and large institutions have $494M invested in Rubius Therapeutics, Inc in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 39 increasing their positions, 33 reducing their positions, and 12 closing their positions.
760% more call options, than puts
Call options by funds: $4.78M | Put options by funds: $556K
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
18% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 33
8% more funds holding
Funds holding: 108 → 117 (+9)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
43% less capital invested
Capital invested by funds: $863M → $494M (-$369M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$3.11M |
| 2 |
Millennium Management
New York
|
+$2.98M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$2.87M |
| 4 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
+$1.91M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$7.47M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.82M |
| 3 |
Rafferty Asset Management
New York
|
-$1.16M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$671K |
| 5 |
Citigroup
New York
|
-$668K |
RUBY Hedge Fund Activity: Q1 2022 in Review
117 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q1 2022, worth a combined $494M — down 43% from $863M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RUBY positions and 12 closed out — a net gain of 9 holders — while 39 added to existing stakes and 33 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $3.11M. The largest seller was State Street, cutting an estimated $7.47M.
- 117 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q1 2022, up from 108 in Q4 2021.
- Funds reported $494M of Rubius Therapeutics, Inc stock for Q1 2022, down 43% quarter-over-quarter.
- 21 funds opened new Rubius Therapeutics, Inc positions in Q1 2022 and 12 closed out, a net change of +9 holders.
- The largest Rubius Therapeutics, Inc buyer in Q1 2022 was Victory Capital Management, an estimated $3.11M added.
- The largest Rubius Therapeutics, Inc seller in Q1 2022 was State Street, an estimated $7.47M sold.
Based on aggregated 13F filings for Q1 2022.